Sanofi invests $700M in Alnylam's RNAi tech; Merck drops RNAi specialist Sirna;

> Sanofi ($SNY) invested $700 million in Alnylam's ($ALNY) RNAi technology. Story

> Merck ($MRK) sold Sirna Therapeutics, its RNAi arm, to Alnylam ($ALNY). Article

> Researchers at the University of North Carolina have come up with a new way to visualize RNA, an advancement that could have future implications for drug delivery. More

> Interface Biologics and Q3 Medical Devices signed an agreement to develop a drug-coated balloon with Interface's Kinesyx technology. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.